Carine Avondo

Carine Avondo

Auto-generated profile, based on publicly available information

Carine Avondo

UR UPJV 7517 MP3CV, CURS, University of Picardie Jules Verne, Amiens, 80054 France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LHLucie Hénaut
Lucie Hénaut
MGMaria Grissi
Maria Grissi
FBFrançois Brazier
François Brazier
MAMaryam Assem
Maryam Assem
SPSabrina Poirot-Leclercq
Sabrina Poirot-Leclercq
JCJean-Marc Chillon
Jean-Marc Chillon
Ischemic stroke is highly prevalent in chronic kidney disease (CKD) patients and has been associated with a higher risk of neurological deterioration and in-hospital mortality. To date, little is known about the processes by which CKD worsens ischemic stroke. This work aimed to investigate the cellular and molecular mechanism associated with ischemic stroke severity in an in vivo model of CKD. CKD was induced through right kidney cortical electrocautery in 8-week-old female C57BL/6 J mice followed by left total nephrectomy. Transient middle cerebral artery occlusion (tMCAO) was performed 6 weeks after left nephrectomy. Twenty-four hours after tMCAO, the infarct volumes were significantly wider in CKD than in SHAM mice. CKD mice displayed decreased neuroscore, impaired ability to remain on rotarod device, weaker muscular strength and decreased prehensile score. Apoptosis, neuronal loss, glial cells recruitment and microglia/macrophages M1 signature genes CD32, CD86, IL-1β, IL-6, MCP1 and iNOS were significantly increased within ischemic lesions of CKD mice. This effect was associated with decreased AMP kinase phosphorylation and increased activation of the NFΚB pathway. Pharmacological targeting of AMP kinase activity, which is known to block microglia/macrophages M1 polarization, appears promising to improve stroke recovery in CKD.

24 March 2023 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Open access
ACAlexandre Candellier
Alexandre Candellier
NINervana Issa
Nervana Issa
MGMaria Grissi
Maria Grissi
TBThéo Brouette
Théo Brouette
CACarine Avondo
Carine Avondo
CVClaire Vézier
Claire Vézier
Calcific aortic stenosis (CAS) is more prevalent, occurs earlier, progresses faster and has worse outcomes in patients with chronic kidney disease (CKD). The uremic toxin indoxyl sulfate (IS) is powerful predictor of cardiovascular mortality in these patients and a strong promoter of ectopic calcification whose role in CAS remains poorly studied. The objective of this study was to evaluate whether IS influences the mineralization of primary human valvular interstitial cells (hVICs) from the aortic valve. Primary hVICs were exposed to increasing concentrations of IS in osteogenic medium (OM). The hVICs' osteogenic transition was monitored by qRT-PCRs for BMP2 and RUNX2 mRNA. Cell mineralization was assayed using the o-cresolphthalein complexone method. Inflammation was assessed by monitoring NF-κB activation using Western blots as well as IL-1β, IL-6 and TNF-α secretion by ELISAs. Small interfering RNA (siRNA) approaches enabled us to determine which signaling pathways were involved. Indoxyl-sulfate increased OM-induced hVICs osteogenic transition and calcification in a concentration-dependent manner. This effect was blocked by silencing the receptor for IS (the aryl hydrocarbon receptor, AhR). Exposure to IS promoted p65 phosphorylation, the blockade of which inhibited IS-induced mineralization. Exposure to IS promoted IL-6 secretion by hVICs, a phenomenon blocked by silencing AhR or p65. Incubation with an anti-IL-6 antibody neutralized IS's pro-calcific effects. IS promotes hVIC mineralization through AhR-dependent activation of the NF-κB pathway and the subsequent release of IL-6. Further research should seek to determine whether targeting inflammatory pathways can reduce the onset and progression of CKD-related CAS.

1 April 2019 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Open access
HIHawraa Issa
Hawraa Issa
LHLucie Hénaut
Lucie Hénaut
JAJeanne Bou Abdallah
Jeanne Bou Abdallah
CBCédric Boudot
Cédric Boudot
GLGaëlle Lenglet
Gaëlle Lenglet
SKSaid Kamel
Said Kamel
Calcific aortic valve disease (CAVD) is the most common heart valve disease in western countries. It has been reported that activation of the calcium-sensing receptor(CaSR) expressed by vascular smooth muscle cells prevents vascular calcification. However, to date, the CaSR's expression and function in cardiac valves have not been studied. The present study sought to evaluate the presence of the CaSR within human valvular interstitial cells (hVICs), assess the CaSR's functionality, and ascertain its involvement in hVIC calcification. Data from Western blot, flow cytometry and immunocytochemistry experiments demonstrated that primary hVICs express the CaSR. The receptor was functional, since the incubation of hVICs with the calcimimetic R-568 significantly increased Ca2+-induced ERK1/2 phosphorylation, and exposure to the calcilytic NPS2143 reduced ERK1/2 activation. A reduction in endogenous CaSR expression by hVICs (using siRNA) was associated with significantly lower levels of Ca2+-induced mineralization (quantified using Alizarin Red staining). Similar data were obtained after the pharmacological inhibition of CaSR activity by the calcilytic NPS2143. In contrast, overexpression of a functional CaSR amplified Ca2+-induced calcification. Pharmacological activation of the CaSR with the calcimimetic R-568 showed similar effects. CaSR's procalcific properties are associated with increased osteogenic transition (as characterized by elevated mRNA expression of bone morphogenetic protein 2 and osterix), and reduced the expression of the calcification inhibitor osteopontin. Histological analysis of 12 human aortic tricuspid valves showed that CaSR expression was greater in calcified areas than in non-calcified areas. These data were confirmed by Western blots. To the best of our knowledge, this study is the first to have demonstrated that hVICs express a functional CaSR. Taken as a whole, our data suggest that activation of the CaSR expressed by hVICs might be a key promoter of CAVD progression.

4 November 2026 in Kidney360
Verified
Journal Article
Open access
GBGérémy Blot
Gérémy Blot
QBQuentin de Berny
Quentin de Berny
LLLoïc Louvet
Loïc Louvet
LVLudivine Vasseur
Ludivine Vasseur
CACarine Avondo
Carine Avondo
LHLucie Hénaut
Lucie Hénaut
Background: Calcific aortic valve disease (CAVD) is prevalent in chronic kidney disease (CKD), yet no pharmacological therapies exist. Preclinical models rarely incorporate CKD–mineral and bone disorder (CKD-MBD) features, limiting translational potential. We aimed to develop a comprehensive preclinical approach to study CKD-associated CAVD, suitable for standardized assessment of therapies on valvular, cardiac, vascular, and skeletal outcomes. Methods: Eight-week-old male Sprague Dawley rats were assigned to a control group (n=17) fed standard chow or an adenine-phosphate group (AP, n=21) fed chow supplemented with 0.3% adenine and 1.15% phosphate. Diets were enriched with 20% lactose and 19% casein to facilitate phosphate absorption and calcium solubility. Cardiac function was evaluated by echocardiography at baseline, week 5, and 9, with concurrent blood sampling. Aortic valve (AV) calcification was assessed by Alizarin Red and Osteosense staining, and aortic calcium quantified using O-Cresolphthalein Complexone. Gene expression in the aorta and left ventricle (LV) was analyzed by RNA-seq at week 9, and bone microarchitecture assessed by micro-CT. Results: AP rats showed progressive increases in serum creatinine, calcium-phosphorus product, and uremic toxins. By week 9, they exhibited significant AV calcification, with reduced valve area and cusp separation. Relative wall thickness and LV histology were preserved, though transcriptomics revealed early priming toward inflammation and fibrosis. AP rats’ aortas showed calcification, osteogenic features and reduced systolic expansion. Bone analysis revealed cortical thinning and increased porosity, while trabecular bone showed reduced trabecular number, increased trabecular spacing, and compensatory thickening. Together with elevated PTH and FGF23 levels, these changes suggest high bone turnover due to secondary hyperparathyroidism and are correlated with the extent of AV calcification. Conclusions: These results underscore the model’s translational relevance, addressing multiple facets of CKD-MBD and supporting its use for preclinical screening of novel therapies targeting CKD-associated cardiovascular calcification.